AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 39300465 — intervention group
Group type: EXPERIMENTAL
Intervention: Water, Sanitation and Hygiene (WASH) intervention
Number of subjects: 2000
Study 39300465 — intervention group
Group type: COMPARATOR
Intervention: Standard national treatment of uncomplicated SAM
Number of subjects: 2000
Study 39300483 — intervention group
Group type: EXPERIMENTAL
Intervention: Enteral cholecalciferol (10,000 IU/kg, max 400,000 IU)
Number of subjects: 766
Study 39300483 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 766
Study 39300513 — intervention group
Group type: EXPERIMENTAL
Intervention: IV secukinumab (6 mg/kg at baseline followed by 3 mg/kg every four weeks)
Number of subjects: 526
Study 39300513 — intervention group
Group type: COMPARATOR
Intervention: IV placebo
Number of subjects: 526
Study 39300513 — intervention group
Group type: EXPERIMENTAL
Intervention: IV secukinumab (3 mg/kg every four weeks after switching from placebo)
Number of subjects: 526
Study 39300513 — intervention group
Group type: EXPERIMENTAL
Intervention: IV secukinumab
Number of subjects: 526
Study 39300529 — intervention group
Group type: EXPERIMENTAL
Intervention: rTMS-active treatment for 10 consecutive days (n=10)
Number of subjects: 20
Study 39300529 — intervention group
Group type: COMPARATOR
Intervention: rTMS-sham treatment for 10 consecutive days (n=10)
Number of subjects: 20
Study 39300529 — intervention group
Group type: EXPERIMENTAL
Intervention: rTMS-active treatment
Number of subjects: 20
Study 39300555 — intervention group
Group type: EXPERIMENTAL
Intervention: Implementation strategies (educational meetings, outcome measure champions, equipment provision, training materials, documentation system adaptation)
Number of subjects: 200
Study 39300596 — intervention group
Group type: EXPERIMENTAL
Intervention: IV secukinumab (6 mg/kg at baseline followed by 3 mg/kg every four weeks)
Number of subjects: 381
Study 39300596 — intervention group
Group type: COMPARATOR
Intervention: Placebo (switched to IV secukinumab at week 16)
Number of subjects: 381
Study 39300596 — intervention group
Group type: EXPERIMENTAL
Intervention: IV secukinumab (continued treatment through week 52)
Number of subjects: 381
Study 39300596 — intervention group
Group type: EXPERIMENTAL
Intervention: IV secukinumab
Number of subjects: 381
Study 39300596 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 381
Study 39300794 — intervention group
Group type: EXPERIMENTAL
Intervention: Dupilumab 300 mg every 2 weeks
Number of subjects: 724
Study 39300794 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 724
Study 39300870 — intervention group
Group type: EXPERIMENTAL
Intervention: Strengthening coping strategies and treatment expectations
Number of subjects: 0
Study 39300911 — intervention group
Group type: EXPERIMENTAL
Intervention: Heart Rate (HR) in women
Number of subjects: 74
Study 39300911 — intervention group
Group type: EXPERIMENTAL
Intervention: Vagal-related Heart Rate Variability (HRV) parameters in women
Number of subjects: 74
Study 39300911 — intervention group
Group type: COMPARATOR
Intervention: Heart Rate (HR) and Vagal-related HRV parameters in men
Number of subjects: 74
Study 39301110 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin D supplementation (20 µg)
Number of subjects: 0
Study 39301110 — intervention group
Group type: COMPARATOR
Intervention: Vitamin D insufficiency (<50 nmol/L)
Number of subjects: 0
Study 39301223 — intervention group
Group type: EXPERIMENTAL
Intervention: Blended Trauma-focused Cognitive Therapy (bTF-CT)
Number of subjects: 17
Study 39301290 — intervention group
Group type: EXPERIMENTAL
Intervention: Active transcranial alternating current stimulation at alpha frequency
Number of subjects: 22
Study 39301290 — intervention group
Group type: COMPARATOR
Intervention: Sham (placebo) transcranial alternating current stimulation
Number of subjects: 22
Study 39301485 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.01% atropine topical eye drop
Number of subjects: 33
Study 39301593 — intervention group
Group type: EXPERIMENTAL
Intervention: Stepped care including behavioural and antidepressant therapy (ADT)
Number of subjects: 391
Study 39301593 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 391
Study 39301726 — intervention group
Group type: EXPERIMENTAL
Intervention: Initial invasive management
Number of subjects: 4617
Study 39301726 — intervention group
Group type: COMPARATOR
Intervention: Conservative management
Number of subjects: 4617
Study 39301872 — intervention group
Group type: EXPERIMENTAL
Intervention: Early stage borderline ovarian tumor patients
Number of subjects: 30
Study 39301872 — intervention group
Group type: COMPARATOR
Intervention: Controls (benign ovarian tumors)
Number of subjects: 30
Study 39301872 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups (patients and controls)
Number of subjects: 30
Study 39301879 — intervention group
Group type: EXPERIMENTAL
Intervention: Erythropoiesis-stimulating agents (ESAs)
Number of subjects: 5348
Study 39301983 — intervention group
Group type: EXPERIMENTAL
Intervention: Simulation-based hand hygiene training
Number of subjects: 60
Study 39301983 — intervention group
Group type: COMPARATOR
Intervention: Theoretical education and demonstration (Control)
Number of subjects: 60
Study 39302128 — intervention group
Group type: EXPERIMENTAL
Intervention: Bedsharing
Number of subjects: 457
Study 39302169 — intervention group
Group type: EXPERIMENTAL
Intervention: DPP Typhoid assay (Chembio) using manufacturer's thresholds
Number of subjects: 385
Study 39302169 — intervention group
Group type: EXPERIMENTAL
Intervention: DPP Typhoid assay (Chembio) at Youden's optimal threshold
Number of subjects: 385
Study 39302169 — intervention group
Group type: COMPARATOR
Intervention: DPP Typhoid assay (Chembio) compared with nine other rapid diagnostic tests
Number of subjects: 385
Study 39302345 — intervention group
Group type: EXPERIMENTAL
Intervention: Baseline [18F]fluorodeoxyglucose PET/CT imaging
Number of subjects: 185
Study 39302345 — intervention group
Group type: EXPERIMENTAL
Intervention: Molecular subtype
Number of subjects: 185
Study 39302514 — intervention group
Group type: EXPERIMENTAL
Intervention: Oropharyngeal exercises
Number of subjects: 40
Study 39302514 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined aerobic and oropharyngeal exercises
Number of subjects: 40
Study 39302514 — intervention group
Group type: COMPARATOR
Intervention: Control group (no exercise)
Number of subjects: 40
Study 39302529 — intervention group
Group type: EXPERIMENTAL
Intervention: CST IV (non-optimal vaginal microbiota)
Number of subjects: 241
Study 39302529 — intervention group
Group type: EXPERIMENTAL
Intervention: CST I (Lactobacillus crispatus-dominated)
Number of subjects: 241
Study 39302529 — intervention group
Group type: EXPERIMENTAL
Intervention: CST III (Lactobacillus iners-dominated)
Number of subjects: 241
Study 39302529 — intervention group
Group type: EXPERIMENTAL
Intervention: Transition from CST III to CST IV
Number of subjects: 241
Study 39302529 — intervention group
Group type: EXPERIMENTAL
Intervention: Transition from CST IV to CST I
Number of subjects: 241
Study 39302529 — intervention group
Group type: EXPERIMENTAL
Intervention: Stable CST trajectory
Number of subjects: 241
Study 39302529 — intervention group
Group type: EXPERIMENTAL
Intervention: Single sample prediction of CST trajectory
Number of subjects: 241
Study 39302614 — intervention group
Group type: EXPERIMENTAL
Intervention: SG 10 mg/kg
Number of subjects: 51
Study 39302678 — intervention group
Group type: EXPERIMENTAL
Intervention: Wearable device intervention
Number of subjects: 74
Study 39302678 — intervention group
Group type: COMPARATOR
Intervention: Usual care (Control)
Number of subjects: 74
Study 39302855 — intervention group
Group type: EXPERIMENTAL
Intervention: Maribavir
Number of subjects: 547
Study 39302855 — intervention group
Group type: COMPARATOR
Intervention: Valganciclovir
Number of subjects: 547
Study 39302924 — intervention group
Group type: EXPERIMENTAL
Intervention: ALVAC+gp120/MF59
Number of subjects: 70
Study 39302924 — intervention group
Group type: EXPERIMENTAL
Intervention: gp120/MF59 alone
Number of subjects: 70
Study 39302924 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 70
Study 39302982 — intervention group
Group type: EXPERIMENTAL
Intervention: CBD-enriched Cannabis Herbal Extract (MPL-001 with a THC:CBD of 1:25), starting at 0.2-0.4 mg/kg of CBD per day and escalating monthly up to 0.8-1.0 mg/kg of CBD per day
Number of subjects: 20
Study 39302982 — intervention group
Group type: EXPERIMENTAL
Intervention: CBD-enriched Cannabis Herbal Extract (MPL-001 with a THC:CBD of 1:25)
Number of subjects: 20
Study 39303189 — intervention group
Group type: EXPERIMENTAL
Intervention: Radiotherapy (RT) with chemotherapy if node-positive
Number of subjects: 68
Study 39303189 — intervention group
Group type: COMPARATOR
Intervention: Transoral robotic surgery (TORS) plus neck dissection (± adjuvant RT/chemoradiation)
Number of subjects: 68
Study 39303200 — intervention group
Group type: EXPERIMENTAL
Intervention: Nivolumab (240 mg once every 2 weeks for up to 12 doses)
Number of subjects: 825
Study 39303200 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 825
Study 39303378 — intervention group
Group type: EXPERIMENTAL
Intervention: Virtual Reality Glasses
Number of subjects: 400
Study 39303378 — intervention group
Group type: EXPERIMENTAL
Intervention: Kaleidoscope
Number of subjects: 400
Study 39303378 — intervention group
Group type: EXPERIMENTAL
Intervention: Distraction Cards
Number of subjects: 400
Study 39303378 — intervention group
Group type: COMPARATOR
Intervention: Control Group
Number of subjects: 400
Study 39303729 — intervention group
Group type: EXPERIMENTAL
Intervention: Decitabine, venetoclax, and ponatinib
Number of subjects: 20
Study 39303788 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose quadrivalent influenza vaccine (QIV-HD)
Number of subjects: 12477
Study 39303788 — intervention group
Group type: COMPARATOR
Intervention: Standard-dose quadrivalent influenza vaccine (QIV-SD)
Number of subjects: 12477
Study 39303806 — intervention group
Group type: EXPERIMENTAL
Intervention: Lower Pao2 targets
Number of subjects: 697
Study 39303988 — intervention group
Group type: EXPERIMENTAL
Intervention: Promoting Resilience in Stress Management (PRISM) intervention
Number of subjects: 0
Study 39303988 — intervention group
Group type: COMPARATOR
Intervention: Control arm
Number of subjects: 0
Study 39304237 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous ferric carboxymaltose (20 mg/kg to a maximum of 1000 mg)
Number of subjects: 1056
Study 39304237 — intervention group
Group type: COMPARATOR
Intervention: Oral ferrous sulphate (200 mg; 65 mg elemental iron) three times daily until 6 weeks postpartum
Number of subjects: 1056
Study 39304237 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous ferric carboxymaltose
Number of subjects: 1056
Study 39304237 — intervention group
Group type: COMPARATOR
Intervention: Oral ferrous sulphate
Number of subjects: 1056
Study 39304238 — intervention group
Group type: EXPERIMENTAL
Intervention: IPTp with dihydroartemisinin-piperaquine plus targeted information transfer intervention
Number of subjects: 1189
Study 39304238 — intervention group
Group type: EXPERIMENTAL
Intervention: IPTp with dihydroartemisinin-piperaquine only
Number of subjects: 1189
Study 39304238 — intervention group
Group type: COMPARATOR
Intervention: IPTp with sulfadoxine-pyrimethamine
Number of subjects: 1189
Study 39304240 — intervention group
Group type: EXPERIMENTAL
Intervention: Mexiletine for 8 weeks
Number of subjects: 60
Study 39304240 — intervention group
Group type: COMPARATOR
Intervention: Lamotrigine for 8 weeks
Number of subjects: 60
Study 39304240 — intervention group
Group type: COMPARATOR
Intervention: Comparison of mexiletine and lamotrigine
Number of subjects: 60
Study 39304241 — intervention group
Group type: EXPERIMENTAL
Intervention: Subcutaneous efgartigimod PH20 (1000 mg weekly for a maximum of 48 weeks)
Number of subjects: 322
Study 39304241 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 322
Study 39304241 — intervention group
Group type: EXPERIMENTAL
Intervention: Subcutaneous efgartigimod PH20
Number of subjects: 322
Study 39304362 — intervention group
Group type: EXPERIMENTAL
Intervention: Biomarker levels before PCI
Number of subjects: 48
Study 39304362 — intervention group
Group type: EXPERIMENTAL
Intervention: Biomarker levels 3-days post-initiating PCI
Number of subjects: 48
Study 39304555 — intervention group
Group type: EXPERIMENTAL
Intervention: Waist-to-height ratio
Number of subjects: 469
Study 39304555 — intervention group
Group type: EXPERIMENTAL
Intervention: Android/gynoid ratio
Number of subjects: 469
Study 39304555 — intervention group
Group type: EXPERIMENTAL
Intervention: Obesity
Number of subjects: 469
Study 39304555 — intervention group
Group type: EXPERIMENTAL
Intervention: Fat mass percentage
Number of subjects: 469
Study 39304555 — intervention group
Group type: EXPERIMENTAL
Intervention: Overweight
Number of subjects: 469
Study 39304589 — intervention group
Group type: EXPERIMENTAL
Intervention: Text
Number of subjects: 254
Study 39304589 — intervention group
Group type: EXPERIMENTAL
Intervention: Webapp
Number of subjects: 254
Study 39304589 — intervention group
Group type: COMPARATOR
Intervention: Text+
Number of subjects: 254
Study 39304589 — intervention group
Group type: COMPARATOR
Intervention: Webapp+
Number of subjects: 254
Study 39304589 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 254
Study 39304604 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise (home-based, individually tailored, moderate intensity, progressive walking, and resistance training)
Number of subjects: 19
Study 39304604 — intervention group
Group type: COMPARATOR
Intervention: Active control (nutrition education)
Number of subjects: 19
Study 39304797 — intervention group
Group type: COMPARATOR
Intervention: Combined androgen blockade (CAB) with goserelin (10.8 mg/3m) and bicalutamide (50 mg/OD)
Number of subjects: 98
Study 39304797 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined androgen blockade (CAB) with goserelin (10.8 mg/3m), bicalutamide (50 mg/OD), and dutasteride (0.5 mg/OD)
Number of subjects: 98
Study 39304797 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined androgen blockade (CAB) with goserelin, bicalutamide, and dutasteride (0.5 mg/OD) in patients with disease progression after prior CAB therapy
Number of subjects: 98
Study 39304918 — intervention group
Group type: EXPERIMENTAL
Intervention: telephone-delivered psychotherapy (t-CETA)
Number of subjects: 20
Study 39304918 — intervention group
Group type: COMPARATOR
Intervention: standard in-person treatment as usual
Number of subjects: 20
Study 39304930 — intervention group
Group type: EXPERIMENTAL
Intervention: HD-tDCS
Number of subjects: 18
Study 39304930 — intervention group
Group type: COMPARATOR
Intervention: Sham stimulation
Number of subjects: 18
Study 39304956 — intervention group
Group type: EXPERIMENTAL
Intervention: Low Socioeconomic Status (SES)
Number of subjects: 106
Study 39304956 — intervention group
Group type: EXPERIMENTAL
Intervention: Reserve capacity (helplessness, self-efficacy, social support)
Number of subjects: 106
Study 39304956 — intervention group
Group type: EXPERIMENTAL
Intervention: Negative emotions (stress and depressive symptoms)
Number of subjects: 106
Study 39304956 — intervention group
Group type: EXPERIMENTAL
Intervention: SES
Number of subjects: 106
Study 39304956 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall model
Number of subjects: 106
Study 39305031 — intervention group
Group type: EXPERIMENTAL
Intervention: Fast-acting insulin therapy
Number of subjects: 467
Study 39305031 — intervention group
Group type: EXPERIMENTAL
Intervention: Model prediction using 196 features including baseline HbA1c, SMBG, sex, etc.
Number of subjects: 467
Study 39305035 — intervention group
Group type: EXPERIMENTAL
Intervention: Individualised comprehensive physical therapy
Number of subjects: 286
Study 39305035 — intervention group
Group type: EXPERIMENTAL
Intervention: Follow-up for extended period (average, 30.71 ± 10.86 months)
Number of subjects: 286
Study 39305035 — intervention group
Group type: EXPERIMENTAL
Intervention: Logistic regression analysis
Number of subjects: 286
Study 39305035 — intervention group
Group type: EXPERIMENTAL
Intervention: Physical therapy
Number of subjects: 286
Study 39305089 — intervention group
Group type: EXPERIMENTAL
Intervention: Survey participants' willingness to pay for the program
Number of subjects: 299
Study 39305089 — intervention group
Group type: EXPERIMENTAL
Intervention: Factors influencing enrollment
Number of subjects: 299
Study 39305089 — intervention group
Group type: EXPERIMENTAL
Intervention: Barriers to enrollment for uninterested individuals
Number of subjects: 299
Study 39305089 — intervention group
Group type: EXPERIMENTAL
Intervention: Facilitators for interested individuals
Number of subjects: 299
Study 39305089 — intervention group
Group type: EXPERIMENTAL
Intervention: Awareness of the DPP prior to the study
Number of subjects: 299
Study 39305160 — intervention group
Group type: EXPERIMENTAL
Intervention: vosoritide (15 μg/kg/day)
Number of subjects: 119
Study 39305340 — intervention group
Group type: EXPERIMENTAL
Intervention: Whole-food, plant-based intervention with moderate exercise (PB+Ex)
Number of subjects: 169
Study 39305340 — intervention group
Group type: COMPARATOR
Intervention: Standard medical care (SMC)
Number of subjects: 169
Study 39305436 — intervention group
Group type: EXPERIMENTAL
Intervention: Atomoxetine (ato) 80 mg
Number of subjects: 21
Study 39305436 — intervention group
Group type: EXPERIMENTAL
Intervention: Atomoxetine and spironolactone (ato-spiro) 80/50 mg
Number of subjects: 21
Study 39305441 — intervention group
Group type: EXPERIMENTAL
Intervention: Relacorilant (100-200 mg/day for up to 12 weeks or 250-400 mg/day for up to 16 weeks)
Number of subjects: 34
Study 39305441 — intervention group
Group type: COMPARATOR
Intervention: Surgery (biochemical remission)
Number of subjects: 34
Study 39305459 — intervention group
Group type: EXPERIMENTAL
Intervention: Acupuncture therapy
Number of subjects: 112
Study 39305459 — intervention group
Group type: COMPARATOR
Intervention: Routine treatment
Number of subjects: 112
Study 39305562 — intervention group
Group type: EXPERIMENTAL
Intervention: CD19 CAR T-cells
Number of subjects: 6
Study 39305562 — intervention group
Group type: COMPARATOR
Intervention: Cytokine release syndrome (CRS) treatment
Number of subjects: 6
Study 39305562 — intervention group
Group type: COMPARATOR
Intervention: Immune effector cell-associated neurotoxicity syndrome (ICANS) treatment
Number of subjects: 6
Study 39305562 — intervention group
Group type: COMPARATOR
Intervention: Overall survival
Number of subjects: 6
Study 39305680 — intervention group
Group type: EXPERIMENTAL
Intervention: Parentbot - a Digital healthcare Assistant
Number of subjects: 118
Study 39305680 — intervention group
Group type: COMPARATOR
Intervention: Standard care only
Number of subjects: 118
Study 39305754 — intervention group
Group type: EXPERIMENTAL
Intervention: Weight loss dietary intervention (specifics not provided)
Number of subjects: 0
Study 39305754 — intervention group
Group type: COMPARATOR
Intervention: Non-transplanted subjects (control group)
Number of subjects: 0
Study 39305808 — intervention group
Group type: EXPERIMENTAL
Intervention: Fentanyl test strips (FTS)
Number of subjects: 509
Study 39305910 — intervention group
Group type: EXPERIMENTAL
Intervention: Stereotactic body radiotherapy (SBRT) followed by two cycles of 200 mg intravenous PD-1 inhibitor, tislelizumab, plus platinum-based chemotherapy.
Number of subjects: 46
Study 39305910 — intervention group
Group type: EXPERIMENTAL
Intervention: Stereotactic body radiotherapy (SBRT) followed by immunochemotherapy.
Number of subjects: 46
Study 39305913 — intervention group
Group type: COMPARATOR
Intervention: Glucocorticoids alone
Number of subjects: 64
Study 39305913 — intervention group
Group type: EXPERIMENTAL
Intervention: Glucocorticoids in combination with immunosuppressive agents or intravenous immunoglobulin
Number of subjects: 64
Study 39306190 — intervention group
Group type: EXPERIMENTAL
Intervention: Young Women's Intervention (educational intervention for young women with newly diagnosed breast cancer and their oncologists)
Number of subjects: 312
Study 39306190 — intervention group
Group type: EXPERIMENTAL
Intervention: Young Women's Intervention
Number of subjects: 312
Study 39306190 — intervention group
Group type: COMPARATOR
Intervention: Contact-time control physical activity intervention
Number of subjects: 312
Study 39306346 — intervention group
Group type: EXPERIMENTAL
Intervention: Apixaban at a reduced dose of 2.5 mg two times per day
Number of subjects: 178
Study 39306346 — intervention group
Group type: COMPARATOR
Intervention: Warfarin therapy adjusted to INR target (2-3)
Number of subjects: 178
Study 39306346 — intervention group
Group type: EXPERIMENTAL
Intervention: Apixaban
Number of subjects: 178
Study 39306349 — intervention group
Group type: EXPERIMENTAL
Intervention: Qure.ai's 'qXR' software for prioritising chest X-ray interpretation.
Number of subjects: 0
Study 39306349 — intervention group
Group type: COMPARATOR
Intervention: Standard care CXRs interpretation without qXR software.
Number of subjects: 0
Study 39306350 — intervention group
Group type: EXPERIMENTAL
Intervention: First-line cessation medications
Number of subjects: 8144
Study 39306350 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 8144
Study 39306350 — intervention group
Group type: EXPERIMENTAL
Intervention: Increased tobacco regulation
Number of subjects: 8144
Study 39306350 — intervention group
Group type: EXPERIMENTAL
Intervention: Lower GDP and more affordable cigarette pricing relative to a country's GDP
Number of subjects: 8144
Study 39306350 — intervention group
Group type: EXPERIMENTAL
Intervention: Country-level variables (GDP, cigarette relative income price, MPOWER score)
Number of subjects: 8144
Study 39306468 — intervention group
Group type: EXPERIMENTAL
Intervention: Liver transplantation plus chemotherapy
Number of subjects: 94
Study 39306468 — intervention group
Group type: COMPARATOR
Intervention: Chemotherapy alone
Number of subjects: 94
Study 39306585 — intervention group
Group type: EXPERIMENTAL
Intervention: Pembrolizumab 10 mg/kg i.v. every 2 weeks or every 3 weeks for ≤2 years
Number of subjects: 834
Study 39306585 — intervention group
Group type: EXPERIMENTAL
Intervention: Pembrolizumab (≥94 weeks)
Number of subjects: 834
Study 39306585 — intervention group
Group type: EXPERIMENTAL
Intervention: Modified PFS for pembrolizumab
Number of subjects: 834
Study 39306585 — intervention group
Group type: EXPERIMENTAL
Intervention: Second-course pembrolizumab
Number of subjects: 834
Study 39306585 — intervention group
Group type: COMPARATOR
Intervention: Ipilimumab 3 mg/kg i.v. every 3 weeks for four cycles
Number of subjects: 834
Study 39306585 — intervention group
Group type: COMPARATOR
Intervention: Ipilimumab
Number of subjects: 834
Study 39306585 — intervention group
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Number of subjects: 834
Study 39306592 — intervention group
Group type: EXPERIMENTAL
Intervention: Mandibular advancement devices (MAD) treatment for OSA, two-piece adjustable appliances, standardized protocol, duration of six years.
Number of subjects: 112